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CD3, CD28-COSTIMULATED TC2 CELLS ABROGATE MARROW REJEC-
TION INDEPENDENT OF GVHD
Erdmann, A.; Jung, U.; Foley, J.; Fowler, D.H. National Cancer Insti-
tute, Bethesda, MD
We previously found that donor CD8+ Tc2 cells abrogate mar-
row rejection independent of GVHD (F1-into-parent murine
model). Because such Tc2 effects likely involve host precursor
CTL clonal deletion by a veto-type mechanism, we hypothesized
that polyclonal Tc2 effectors would prevent rejection. To test this
hypothesis, CB6F1 donor CD8 cells were stimulated with anti-
CD3, anti-CD28 in cytokine conditions promoting Tc1 or Tc2
differentiation. Tc1 cells produced INF-g without IL-4; Tc2 cells
produced IL-4 with reduced IFN-g. Tc1 cells utilized fas-based
cytolysis, whereas Tc2 cells utilized primarily perforin-based
cytolysis. Sublethally irradiated (700 cGy) B6 hosts rejected F1
marrow. Marrow supplementation with F1 Tc1 cells prevented
rejection in 4/8 recipients, whereas 9/9 Tc2 recipients alloengraft-
ed (median 92% donor chimerism) [Tc2 > Tc1; p=0.013]. Because
Tc1 and Tc2 cells utilize different effector mechanisms, we also
predicted that a Tc1/Tc2 cell mix might synergistically abrogate
rejection; contrary to our hypothesis, Tc1/Tc2 recipients had a
higher rate of rejection than Tc2 recipients. Also, given the pro-
posed veto-type mechanism, we predicted that F1 Tc2 cells would
effectively prevent rejection if administered remote from the mar-
row. Contrary to this hypothesis, delaying Tc2 administration 24
hours post-transplant increased graft rejection, indicating that
host-versus-graft rejection responses mature rapidly in vivo.
Extending these results, we also evaluated CD3, CD28-generated
Tc2 cells in models having maximal GVHD potential (irradiated
parent-into-F1 transplantation). In this setting, recipients of poly-
clonal Tc2 cells had transient weight loss and minimal histologi-
cally-deﬁned GVHD (median score of 1; maximal GVHD score
of 16). CD3, CD28-generated Tc2 cells therefore potently abro-
gate marrow rejection by a non-host reactive mechanism that can
be optimized by Tc2 administration early post-BMT. Because
CD3, CD28-generated Tc2 cells are associated with minimal
GVHD even in settings of maximal alloreactivity, this population
holds promise as a strategy for preventing graft rejection with
reduced GVHD.
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ENGRAFTMENT OF NONMYELOABLATIVE HEMATOPOIETIC STEM
CELL TRANSPLANTS (HSCT) USING MARROW AND PBSC FROM 10/10
HLA ANTIGEN MATCHED UNRELATED DONORS (URDS) FOR
PATIENTS INELIGIBLE FOR CONVENTIONAL HSCT
Maris, M.B.1,2; Niederwieser, D.6; Sandmaier, B.1,2; Maloney, D.1,2;
Shizuru, J.3; Petersdorf, E.1,2; Blume, K.3; Pulsipher, M.4;
McSweeney, P.5; Chauncey, T.1,8; Storer, B.1,2; Slattery, J.1,2;
Woolfrey, A.1,2; Agura, E.7; Hegenbarth, U.6; Feinstein, L.1,2;
Little, M.1; Anasetti, C.1,2; Storb, R.1,2 1. Fred Hutchinson Cancer
Research Center, Seattle, WA; 2. University of Washington, Seattle,
WA; 3. Stanford University, Palo Alto, CA; 4. University of Utah, Salt
Lake City, UT; 5. University of Colorado, Denver, CO; 6. University of
Leipzig, Leipzig, Germany; 7. Baylor University, Dallas, TX; 8. Seat-
tle Veterans Administration Medical Center, Seattle, WA
The efﬁcacy of URD donor nonmyeloablative HSCT was inves-
tigated in 77 pts with hematologic malignancies who were ineligi-
ble for conventional HSCT because of age and/or comorbid con-
ditions. The transplant regimen used ﬂudarabine 30mg/m2/day x
3 and 2 Gy TBI on the day of URD HSCT followed by postgraft-
ing immunosuppression with cyclosporine and mycophenolate
mofetil. URD selection was based on serologic matching for
HLA- A, B, and C and allele level matching for HLA- DRB1 and
DQ. The median pt age was 53 (range 4-69) yrs and the median
follow up was 6.0 (range 0.6-19) months. Seventy percent of pts
had previous intensive chemotherapy, 25% had previous autolo-
gous and 4% previous allogeneic HSCT. PBSC was the source of
HSCs in 60 and marrow in 17 pts. Initial donor T cell engraft-
ment (> 5%) was documented in 89% of pts. Median donor T cell
chimerisms on days 28, 56 and 84 were higher in PBSC recipients
compared to marrow recipients (p= .06, .06 and .05, respectively).
Granulocyte and marrow donor chimerism values were not signif-
icantly different at any time point. Sustained donor engraftment
occurred in 77% of pts and was more frequent for PBSC (50/60)
compared to marrow (10/17) recipients. Rejection was associated
with patient diagnoses (p= .003) and stem cell source (p= .03). Fac-
tors that reduced the risk of rejection included preceding
chemotherapy (p= .09) and conventional HSCT (p= .02). HLA
class I mismatch (5/41 studied pairs) was not associated with rejec-
tion (p= 0.31). KM estimates of survival and PFS at 1 year for
recipients of PBSC vs marrow were: 49% vs 17% and 43% vs 8%
(p=.04 and .003). In summary, nonmyeloablative HSCT using
URDs is feasible in pts with hematologic malignancies not eligible
for conventional HSCT. Compared to marrow, PBSC provides
superior engraftment, disease free and overall survivals. 
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COMBINED USE OF SBA-E- T CELL DEPLETED BMT(TCDBMT) AND
DONOR LEUKOCYTE INFUSIONS(DLI) FOR THE TREATMENT OF
CHRONIC MYELOGENOUS LEUKEMIA(CML): 10 YEAR EXPERIENCE
AT MSKCC
Papadopoulos, E.B.; Young, J.W.; Castro-Malaspina, H.;
Jakubowski, A.; Childs, B.H.; Boulad, F.; Kernan, N.A.; Small, T.N.;
Collins, N.H.; O’Reilly, R.J. Memorial Sloan-Kettering Cancer Center,
New York, NY
TCDBMT reduces the incidence and severity of acute and
chronic GvHD. However, in pts with CML, it leads to high
relapse rates. We have used a combined approach utilizing
TCDBMT followed by DLI, if necessary, in the treatment of
84 pts with CML. Median age: 41 yrs. Median time from diag-
nosis to BMT: 9.7 mos. All received TCDBMT from HLA-
identical siblings after HFTBI, thiotepa, cyclophosphamide,
+/- anti-thymocyte globulin for graft rejection prophylaxis. Pts
were monitored for evidence of relapse by RT-pcr, karyotype,
FISH, morphology. Pre-10/1/95, pts became eligible for DLI
therapy after cytogenetic or hematologic relapse. Post-10/1/95,
pts with minimal residual disease (MRD) became eligible. DLI
were administered in doses escalated at 0.5 log10 increments at
1-6 mo intervals, beginning at 107CD3+ cells/kg for hemato-
logic relapse, 0.3 x 107 CD3+ cells/kg for cytogenetic or
molecular relapse. Forty-six pts received DLI for
molecular(n=18), cytogenetic(n=15), hematologic(n=11)
relapse. Median follow up: 56 mos. Overall survival and cur-
rent leukemia free survival (CLFS) are 67% and 66% at 5 yrs.
Cumulative incidence of acute GvHD(II-IV) was 6% and 5%
for chronic GvHD. Molecular CR were achieved in 94%, 88%,
76% of pts treated for molecular, cytogenetic, hematologic
phase recurrence, respectively. Cumulative doses of T cells
required to induce remission in greater than 50% of cases
increased from 0.3 x 107/kg in pts treated for molecular recur-
rence to 1.6-1.8 x 108/kg for pts in hematologic relapse. With
pre-emptive treatment for molecular recurrence (>10/1/95),
cumulative risk of chronic GvHD decreased from 11% to 2%,
probability of cytogenetic relapse fell from 46% to 22%, CLFS
rose from 60% to 70%. If transplanted within 1yr of diagnosis,
CLFS increased from 70% to 79%. If monitored and treated
for MRD, CML pts can achieve durable molecular remissions
following TCDBMT +/- DLI with minimal risk of acute or
chronic GvHD.
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EARLY LYMPHOCYTE RECOVERY CORRELATES WITH SUPERIOR
SURVIVAL AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATIO
Porrata, L.F.; Gertz, M.A.; Inwards, D.J.; Litzow, M.R.; Lacy, M.Q.;
Tefferi, A.; Dispenzieri, A.; Ansell, S.M.; Micallef, I.N.;
Markovic, S.N. Mayo CLinic, Rochester, MN
Early absolute lymphocyte count (ALC) recovery after allogene-
ic bone marrow transplantation has been associated with
improved survival. Individual cohort analysis demonstrated that
ALC equal or greater than 500 cells/ul by day 15 post-autologous
stem cell transplantation (ASCT) as a signiﬁcant prognostic factor
for overall survival (OS) and progression-free survival (PFS). In
this study, we pooled data of patients transplanted by ASCT and
evaluated the impact of early ALC recovery on OS and PFS while
taking into account inherent differences based on the patients’
underlying disease. We analyzed 386 consecutive patients trans-
planted at Mayo Clinic, Rochester, Minnesota between 1985 and
2000. The ALC threshold was determined at 500 cells/ul at day
15 post- ASCT. Of the 386 patients, 126 patients had multiple
myeloma, 104 patients non-Hodgkin’s lymphoma, 82 patients
Hodgkin’s disease, 45 patients acute myelogenous leukemia, and
29 patients metastatic breast cancer. Overall, 210 males and 176
females were included in the study with a median age at time of
transplant of 49 years (range 12-73 years). The median follow-up
was 16 months with a maximum of 158 months. The median OS
was signiﬁcantly better for the 203 patients that reached an ALC
equal or greater than 500 cells/ul by day 15 post-ASCT compared
with the 183 patents that did not (medians: not yet reached vs 12
months, respectively, p < 0.0001; RR = 0.15, 95% c.i. = 0.10 –
0.21). Similarly, PFS was significantly better in patients that
reached an ALC equal or greater than 500 than those who did not
(medians: 49 months vs 8 months, respectively, p < 0.0001; RR =
0.25, 95% c.i. = 0.19 – 0.33). ALC equal or greater than 500
cells/ul on day 15 after ASCT is a signiﬁcant prognostic indicator
of improved OS and PFS for patients undergoing ASCT, regard-
less of disease type.
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SIGNIFICANT EX VIVO EXPANSION AND ACTIVATION OF
CYTOKINE/ANTIBODY T-INDUCED LYMPHOCYTES (CATIL) FROM
CRYOPRESERVED UMBILICAL CORD BLOOD (UCB): POTENTIAL FOR
CELLULAR IMMUNOTHERAPY POST UCB TRANSPLANT
Cairo, M.S.1; Ayello, J.1; Kurtzberg, J.2; van de Ven, C.1 1. Children’s
Hospital of New York Presbyterian, Columbia University, New York,
NY; 2. Duke University, Durham, NC
The number of active T cell subsets in UCB limits its use post
transplant for suspected relapse and/or post-transplant lympho-
proliferative disorder (Cairo et al Blood 90:4665, 1997). We previ-
ously demonstrated ex vivo expansion and activation (EVEA) of T
cell subsets from fresh UCB using IL-2 + IL-12 + anti-CD3 + IL-
7 (Robinson et al, Blood 94(10):571a, 1999). We now report
EVEA of CATIL from cryopreserved UCB for potential adoptive
cellular immunotherapy. Cryopreserved UCB MNCs were
thawed (TUCB), resuspended in AIM-V supplemented media
(CBM) and incubated overnight in 5% CO2, 37 o. Nonadherent
cells were cultured in serum-free cocktail of CBM alone (control)
or CBM with 5 ng/ml IL-2 + 10 ng/ml IL-12 + 50 ng/ml anti-
CD3 + 10 ng/ml IL-7 (CBM-2/12/ab3/7) for 48 hours at 37oC,
5% CO 2. Immunophenotyping, cytotoxicity and proliferation
assays were performed. A signiﬁcant increase was demonstrated in
TUCB cultured in CBM-2/12/ab3/7 vs. control in the following
parameters: proliferation, cytotoxicity, CD3+ population,
CD45RO expression and CD4+/CD25+ and CD8+/CD25+ sub-
sets (see table). Cultured CD3+ T cells in CBM-2/12/ab3/7
showed a signiﬁcant increase in the TH1 subset (IFN-γ) vs control
(9.39±0.48 vs 3.02±0.54%, p<0.001, n=7). Thus, CBM-2/12/ab3/7
cocktail significantly enhanced proliferative capacity, expansion
and activation of CATIL from TUCB. This suggests that ex vivo
generation of DLI from TUCB may be feasible; however, further
studies should be performed to address safety and efﬁcacy.
GVH/GVL
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HUMAN GENOME-DERIVED PROTEIN, REPIFERMIN (KERATINOCYTE
GROWTH FACTOR 2, KGF-2), REMEDIATES GRAFT-VERSUS-HOST
DISEASE WHILE PRESERVING A GRAFT-VERSUS-LEUKEMIA
RESPONSE
Clouthier, S.G.1; Connolly, K.2; Ferrara, J.L.1 1. University Of Michi-
gan, Ann Arbor, MI; 2. Human Genome Sciences, Inc., Rockville, MD
Graft-versus-host disease (GVHD) is the principal confounding
factor following allogeneic bone marrow transplantation (BMT).
We investigated a novel human recombinant keratinocyte growth
factor, repifermin (KGF-2, HGS, Inc.), in the well-defined B6
into B6D2F1 murine BMT model in an effort to ameliorate
GVHD. Recipients were conditioned with 1500 cGy TBI on day
0. KGF-2 (5mg/kg) was administered via intra-peritoneal injec-
tion from days -3 to +7. Recipients received 5.0 million bone mar-
row cells and 0.5 million splenic T cells from B6 or B6D2F1
donors. Six week post-BMT survival was significantly increased
with KGF-2 administration (65% v 18%, P = 0.007). The severity
of GVHD (measured by weight loss, skin and fur changes, mobili-
ty and posture) was attenuated in KGF-2 treated mice (4.0 ± 0.2 v
5.6 ± 0.2, P = 0.003). Seven days post-transplantation, KGF-2
treated sera had significantly lower LPS and TNFα levels than
control-treated allogeneic mice (See table). In contrast, serum
INFγ levels were unaffected by KGF-2 administration. Other
indices of donor T cell responses (cellular proliferation, cytolytic
effector function and IL-2 production) were equivalent in KGF-2
and control-treated mice. To test whether KGF-2 preserves GVL,
2,000 P815 leukemia cells were added to the innoculum on day 0.
All recipients of T cell depleted marrow died with macroscopic
evidence (liver/spleen nodules) of leukemia by day 18. KGF-2
increased leukemia-free survival compared to control-treated allo-
geneic mice 28 days after BMT (66% v 33%, P = 0.04). KGF-2
thus appears to preserve potent GVL while reducing mortality of
acute GVHD in this murine BMT model and has important
implications for clinical transplantation.
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CD25+ IMMUNOREGULATORY CELLS OF DONOR ORIGIN SUPPRESS
ALLOREACTIVITY AFTER BMT
Johnson, B.D.; Stankowski, M.C.; Truitt, R.L. Medical College of Wis-
consin, Milwaukee, WI
We have identiﬁed donor-derived Thy1+ αβTCR+ CD4+ regula-
tory T cells that suppress graft-versus-host (GVH) reactivity
induced by donor leukocyte infusion (DLI) after BMT. These
cells develop in the recipient thymus and they may play an impor-
tant role in the maintenance of donor-host tolerance after allo-
geneic BMT. Since CD40-CD40L and B7-CD28 interactions
have both been implicated in the generation of regulatory T cells,
we tested whether either of these pathways have a role in genera-
tion of the regulatory cells identiﬁed in our studies. Lethally irra-
diated AKR recipients (H-2k, Thy1.1+) were transplanted with T-
depleted BM from C57BL/6 mice (H-2b, Thy1.2+) that lacked
CD40L or CD28. Recipients of marrow from CD40L knockout
mice did not develop acute GVHD after DLI suggesting that
CD40L-CD40 interactions were not involved in generation of the
regulatory T cells. In contrast, recipients of marrow from CD28
knockout mice developed lethal GVHD. GVHD was accompa-
nied by body weight loss, and elevated percentages of donor T
cells from the DLI could be detected in the peripheral blood of
these mice one week after DLI as compared to mice transplanted
with normal BM and DLI. These data indicated that B7-CD28
interactions are critical for the generation of the immunoregulato-
ry T cells after BMT. CD4+25+ regulatory T cells have been
described in both rodents and humans, and B7-CD28 costimula-
tion has been shown to be essential for generation of these cells.
To determine whether CD25+ regulatory T cells were responsible
for the regulatory cell activity in our studies, AKR recipients were
transplanted with marrow from CD25 knockout mice. In prelimi-
nary experiments, mice transplanted with CD25 knockout BM
developed severe and lethal GVHD after DLI, suggesting that
CD4+25+ regulatory T cells are crucial to the suppression of GVH
reactivity after allogeneic BMT.
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TARGETING HOST ANTIGEN-PRESENTING CELLS PRE-TRANSPLANT
REDUCES GRAFT VERSUS HOST DISEASE
Chan, G.W.; Gorgun, G.; Miller, K.B.; Foss, F.M. New England
Medical Center, Boston, MA
Murine models of allogeneic bone marrow transplantation
demonstrate that antigen-presenting cells (APCs) of host origin
may initiate graft versus host disease (GVHD). Inactivating host
APCs may reduce GVHD without compromising a graft versus
malignancy (GVM) effect. We correlated APC chimerism with
GVHD in patients following a reduced intensity preparative regi-
men. High-risk patients (n=48) with various malignancies received
photophoresis, pentostatin, and reduced dose total body irradia-
tion followed by an unmanipulated allogeneic stem cell infusion
and standard cyclosporin and methotrexate GVHD prophylaxis.
At a median follow-up of 235 days post-transplant (range 8 to 672
days), 36 patients (75%) are alive. Full donor chimerism occurred
in 42 out of 47 evaluable patients (89%). Actuarial one year overall
survival was 68%. Grade II-IV acute GVHD and extensive chron-
ic GVHD occurred in only 3 patients (6%). Peripheral blood
APCs at day+100 were stimulated with GM-CSF and IL-4 and
confirmed by flow cytometry using CD80, CD123, CD83, and
CD86. APC polymorphism was analyzed with DNA-PCR using
highly polymorphic STR. In all patients with limited or no acute
or chronic GVHD, APCs were all of donor origin (n=18). In one
patient with grade II-IV acute GVHD and extensive chronic
GVHD, all APCs were of host origin. Similar results were
obtained in patients (n=3) who underwent a conventional allo-
geneic preparative regimen. We conclude that persistence of host
APCs post-transplant is associated with the development of grade
II-IV acute GVHD and extensive chronic GVHD in both a pho-
tophoresis-based reduced intensity preparative regimen and a con-
ventional preparative regimen. We hypothesize that our prepara-
tive regimen may target host APCs pre-transplant, reducing the
incidence of GVHD. Host APCs may be important in the devel-
opment of both acute and chronic GVHD.
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ENHANCED ALLOSTIMULATORY ACTIVITY OF ANTIGEN-PRESENTING
CELLS IN OLD MICE ACCELERATES GRAFT-VERSUS-HOST DISEASE
Ordemann, R.; Hutchinson, R.; Friedman, J.; Burakoff, S.; Reddy, P.;
Duffner, U.; Chen, L.; Teshima, T.; Ferrara, J. University of Michi-
gan, Ann Arbor, MI
Acute GVHD is more severe in old BMT recipients but the
mechanisms of this association are poorly understood. Using
murine GVHD models we demonstrated an increase in acute
GVHD severity in the B6 → B6D2F1 system. Acute GVHD mor-
tality in very old (22-24 months)was significantly higher vs old
(14-16 months) mice (p=0.02) and in old significantly higher vs
young (2-4 months) mice (p=.001). In the B10.BR → CBA system
old mice (12-14 months) died significantly more rapidly than
young (2 months) mice (p=0.01). Scores of GI tract histopathology
were also signiﬁcantly worse (pathology score 7.5+1.8 vs 17.5+1.2,
p<.03). Aged BMT recipients exhibited significant increases in
LPS and TNF-α in serum. In non irradiated old B6D2F1 mice,
both total and CD4+ T cell expansion was signiﬁcantly increased
(p<.03). Donor T cells proliferated more and made more IFN-γ to
old host APCs than to young host APCs in vitro. FACS analysis
revealed that BM derived DCs from old mice expressed consis-
tently increased MHC class II. We created BM B6D2F1 chimeras
using syngeneic BM from old (o) donors aged 18 months or young
(y) donors aged 2 months following 11 Gy TBI. Three months
later after a second BMT GVHD mortality was significantly
greater in “aged APC” mice (p<0.003), clinical score was higher
and donor T cell expansion was increased. We conclude that
increased GVHD in old recipients is due to augmented donor T
cell activation by aged host APCs with increased allostimulatory
capacity representing a novel mechanism for this association.
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TREATMENT OF GRAFT-VS-HOST DISEASE AFTER ALLOGENEIC T
CELL IMMUNOTHERAPY USING SELECTIVE DRUG-INDUCED APOPTO-
SIS OF DONOR T CELLS
Gaschet, J.M.; Zhang, J.; Pollock, R.; Clackson, T. ARIAD Pharma-
ceuticals Inc, Cambridge, MA
Graft-versus-host disease (GvHD) remains a major complication
of allogeneic bone marrow transplantation. Donor T cells are
responsible for the development of GvHD but also provide a
beniﬁcial graft-versus-tumor effect (GvT), and are critical for suc-
cessful engraftment. This has led to strategies for modifying
donor T cells to allow their selective elimination should a patient
develop GvHD. Initial studies used the herpes simplex virus
thymidine kinase (HSV-TK)/ganciclovir (GCV) approach, but
this is limited by TK immunogenicity and the need to use GCV
for antiviral therapy in certain patients. We previously reported
the development of AP1903-Fas system, based on drug-induced
apoptosis (Thomis et al., Blood 2001 97:1249). T cells are engi-
neered to express a chimeric protein comprising a cell surface
marker (LNGFR), the signalling domain of the Fas gene, and two
copies of a drug binding domain (FKBP). This fusion protein is
derived entirely from human components to minimize immuno-
genicity. Treatment of engineered T cells with the bivalent
“dimerizer” drug AP1903, crosslinks the fusion proteins and leads
to rapid and potent apoptosis. Fas-engineered human T cells
retain anti-tumor and immune functions. In a recent phase 1 trial
in human volunteers, AP1903 was shown to be safe, well-tolerated
and to demonstrate favorable pharmacokinetics (Iuliucci et al., J
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Clin Pharm. 2001 41:870). For clinical use of the AP1903-Fas sys-
tem to combat GvHD, we have established stable high titer pro-
ducer cell lines to provide retroviral vector for ex vivo transduc-
tion of T cells, using the GALV-based PG13 packaging cell line.
Human T cells transduced with the resulting vector can be
obtained at high purity via immunomagnetic isolation procedures
using an anti-LNGFR monoclonal antibody, and the puriﬁed cells
can be efﬁciently killed by AP1903 treatment. The latest pre-clini-
cal and clinical data of AP1903-Fas T cell immunotherapy for the
control of GvHD will be presented.
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DEPLETION OF DONOR CD11B+ DENDRITIC CELLS RESULTS IN
ENHANCED DONOR-DERIVED IMMUNE RECONSTITUTION AFTER
ALLOGENEIC BMT
Li, J.; Giver, C.; Waller, E.K. Winship Cancer Institute, Emory Uni-
versity Medical School, Atlanta, GA
Background: Host dendritic cells have been shown to be impor-
tant in the initiation of GvHD after allogeneic bone marrow
transplantation [Shlomchik, et al, 1999 Science 285:412]. Recent
clinical data indicates that increased numbers of type 2 dendritic
cells in the bone marrow allograft leads to decreased chronic graft
versus host disease (GvHD) and increased relapse among patients
with hematological malignancy receiving allogeneic BMT from
HLA matched siblings [Waller, et al, 2001 Blood 97:2948]. We
tested the hypothesis that removal of donor type 2 dendritic cells
would affect donor-derived immunity in a mouse model of MHC
mis-matched BMT. Methods: CD11c+ cells from the BM of
CD45.2+ C57BL/6 (H2b) donors were depleted using MACS
immno-afﬁnity columns. B10.BR (H2k ) mice were lethally irradi-
ated (11 Gy) then transplanted with 5 x 106 BM cells alone or a
combination of 1 x 106 splenocytes from congenic CD45.1+
C57BL/6 donors and 5 x 106 BM cells that were 1) un-manipulat-
ed; 2) partially depleted of CD11c+ DC; or 3) fully depleted of
CD11c+ DC. Results: CD11c depletion did not significantly
change the content of Lin-, Sca-1+ c-kit+ hematopoietic progeni-
tor cells or BM T-cells. Recipients of fully or partially CD11c
depleted BM alone had no evidence of GvHD and had 100%
post-transplant survival. Recipients of the combination of donor
splenocytes and CD11c-depleted BM showed increased weight
loss post-transplant consistent with GvHD compared to recipients
of allogeneic splenocytes and un-maipulated BM. The prolifera-
tion of donor T-cells derived from the un-manipulated CD45.1+
C57BL/6 donor splenocytes was inversely proportional to the
content of CD11c+ cells in the donor BM. CD11c-depletion of
donor BM increased the graft versus tumor effect of C57BL/6
donor splenocytes against a B10.BR T-cell lymphoma cell line.
Conclusions: Donor CD11c+ DC in the BM allograft appear to
suppress post-transplant cellular immune reconstitution; CD11c+
DC removal enhances GvL/GvHD.
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INTERLEUKIN-18 REDUCES ACUTE GRAFT-VERSUS-HOST DISEASE
BUT PRESERVES GRAFT-VERSUS-LEUKEMIA EFFECT AFTER ALLO-
GENEIC BONE MARROW TRANSPLANTATION
Reddy, P.; Teshima, T.; KuKuruga, M.; Ordemann, R.; Liu, C.;
Lowler, K.; Ferrara, J.L. University of Michigan Comprehensive Can-
cer Center, Ann Arbor, MI
We investigated the role of IL-18 in acute GVHD using a well
characterized murine bone marrow transplant (BMT) model (B6
into B6D2F1, 2x106 donor T cells and 5x106 BM cells after
1300cGY TBI). Blockade of IL-18 with 10µg/day of anti-IL-18
MAb (days -1 to +3) accelerated acute GVHD related mortality
(P<0.05) and was associated with higher levels of serum LPS and
TNF-α (P<0.05). In contrast, 1µg/day of rmIL-18 (-2 to +2)
improved survival (75% v 15%, P<0.001) and caused reduction in
serum levels of TNF-α, LPS, and GVHD related histopatholo-
gy(P<0.05).Surviving mice showed complete donor engraftment,
thus ruling out graft rejection and mixed chimerism as causes for
decreased GVHD. Further investigation showed that IL-18 atten-
uated donor T cell expansion in the ﬁrst week after BMT by 50%
and caused increased Fas expression on donor T cells (64 ± 5% v
48± 7%, P<0.05) as well as greater apoptosis (annexin V+ donor T
cells: 44 ± 6% v 24 ± %, P<0.05). When Fas-/- deﬁcient (lpr) or
IFN-γ -/- mice were used as donors, rmIL-18 administration did
not prevent GVHD mortality, conﬁrming the role of donor IFN-
γ and Fas in this effect. We next investigated whether IL-18 can
maintain GVL effect using the same model and by injecting recip-
ients with host-type (H-2d) P815 mastocytoma cells at the time of
BMT. Syngeneic BMT recipients died from leukemia by day 21
whereas control- and IL-18-treated allogeneic animals effectively
rejected their leukemia ( gross morphology and ﬂow cytometry),
and IL-18 signiﬁcantly improved leukemia free survival at day 50
(60% vs 10%, P< 0.04). Taken together, our results demonstrate
that early administration of IL-18 preserves the GVL effects of
allogeneic BMT but reduces acute GVHD by increasing Fas
mediated apoptosis of donor T cells early after BMT and donor
derived IFN-γis required for this protective effect.
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REGULATORY T CELLS ACTIVELY SUPPRESS GVHD AND PROMOTE
LYMPHOID RECONSTITUTION IN A MHC CLASS I/II DISPARATE
MURINE BMT MODEL
Marks, L.; Levy, R.B. University of Miami School of Medicine,
Miami, FL
We examined the ability of CD4+CD25+ cells to facilitate reconsti-
tution and suppress GVHD responses in vivo following an allogene-
ic BMT across a complete MHC class I/II donor mismatch.
BALB/C mice received 7 x 106 unfractionated B6 BM cells only
(Gr.A), or in combination with 5 x 105 CD4+CD25+ enriched (Gr.B)
or 5 x 105 CD4+CD25- enriched (Gr.C) T cells. Recipients were
conditioned with 8.5 Gy 1 hour prior to the BMT. Acute GVHD
developed in Gr.C, with 100% mortality (n=6) by day 25 post-BMT.
No lethality occurred in Gr.A or Gr.B recipients. However, signs of
GVHD (diarrhea, haunched posture, rufﬂed fur) began to develop
by 6 weeks post-transplant in mice that received BM alone. These
observations were supported by analysis of the reconstitution of the
predominately donor lymphoid compartment in these recipients.
Approximately 6 weeks post-BMT, Gr. B mice that had received BM
and Treg+ cells had fully reconstituted their splenic compartment
and possessed approximately 3X greater spleen cell numbers than
Gr.A mice. At this same time period, marginal thymic tissue was
detected in Gr. A (0-1 x 107 cells) while thymi of Treg+ recipients
was readily detected (4.4–5.9 x 107 cells). Splenic CD4/CD8 ratios
were 1:1 and 3:1 respectively in Gr.A and Gr.B. Furthermore, 2-4X
the percentage of CD44hi T cells were present in the spleen and LN
indicative of an activated phenotype (CD44hiCD62Llo) in Gr.A mice
compared to Gr.B. In summary, utilizing a sensitive model for
GVHD induction across a complete MHC class I/II genetic dispari-
ty, the results demonstrate that in contrast to CD4+CD25- T cells,
highly enriched CD4+CD25+ (>95%) T cells; a) mediate minimal
GVHD b) suppress GVHD induction by syngeneic BM cells c) pro-
mote lymphoid engraftment by syngeneic progenitor populations.|
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T CELLS FROM CCR5 KNOCKOUT MICE INDUCE ACCELERATED
ACUTE GRAFT-VERSUS-HOST DISEASE LETHALITY AFTER ALLOGENE-
IC BMT IN MICE
Murphy, W.J.1; Wang, Z.1; Welniak, L.1; Kuziel, W.3; Blazar, B.R.2
1. National Cancer Institute at Frederick, Frederick, MD; 2. Universi-
ty of Minnesota Cancer Center, Minneapolis, MN; 3. University of
Texas at Austin, Austin, TX
Graft-versus-host disease (GVHD) is of signiﬁcant concern after
allogeneic bone marrow transplantation (BMT). Acute GVHD
has a complex etiology which includes participation of inﬂamma-
tory processes which contribute to tissue destruction and patholo-
gy. “Chemotactic cytokines” or chemokines play important roles
in inﬂammation involving a variety of immune cell-types. Block-
ade of chemokines may therefore be of use in ameriolating
GVHD pathology. We wanted to ascertain the role of a class of
chemokines using the CC-chemokine receptor, CCR5, in acute
67B B & M T
Oral Presentations
GVHD. The ligands for CCR5 include MIP-1 alpha, MIP-1 beta,
and RANTES. Previous studies have demonstrated that CCR5
KO mice have impaired macrophage function and enhanced T cell
responses. T cells from CCR5 knockout(KO) mice were trans-
ferred into lethally irradiated fully allogeneic recipients. Effects on
GVHD were then determined as evidenced by effects on survival,
histological assessment of pathology, and weight loss characteristic
of acute GVHD. Mice receiving BMC alone from CCR5 KO
mice reconstituted normally. Surprisingly, recipients receiving T
cells from CCR5 KO mice succumbed to acute GVHD to a more
acclerated extent compared to mice receiving T cells from control
donors. Increased weight loss was also observed in these groups.
Assessment of the extent of donor T cell chimerism in these mice
revealed that greater numbers of donor CD8+ T cells were pres-
ent in the spleens of the mice receiving the T cells from the CCR5
KO donors. Heightened responses to T cell mitogens such as Con
A were also observed in these recipients after BMT. These results
suggest that CCR5 plays an important role in down-regulating T
cell function and responses in acute GVHD.
HISTOCOMPATIBILITY/ALTERNATIVE STEM
CELL SOURCES
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IMMUNOMODULATORY EFFECT OF CTLA4-IG WITH DONOR PBMC
INFUSION ON HAPLOIDENTICAL NONMYELOABLATIVE
HEMATOPOIETIC STEM CELL TRANSPLANT WITH 200 CGY TOTAL
BODY IRRADIATION
Fukuda, T.; Santos, E.B.; Bethge, W.; Panse, J.; Storb, R.; Sand-
maier, B.M. Fred Hutchinson Cancer Research Center, Seattle, WA
We have developed a nonmyeloablative hematopoietic stem
cell transplant (NMSCT) regimen consisting of 200 cGy TBI
before and MMF/CSP given after transplant to control both
graft-versus-host and host-versus-graft reactions in dog leuko-
cyte antigen (DLA)-identical littermate recipients. Treatment
of recipients with CTLA4-Ig, which induces anergy of T-cells
by blocking the B7/CD28 costimulatory signal, allowed us to
lower the TBI dose to 100 cGy in DLA-identical NMSCT.
Here, we studied the immunomodulatory effect of CTLA4-Ig
with donor PBMC infusion in facilitating engraftment of hap-
loidentical donor cells after NMSCT. Recipient dogs were
administered CTLA4-Ig (provided by Repligen, Boston, MA)
4-10 mg/kg for 7 days together with 1x107/kg donor PBMC
given on two days before 200 cGy TBI on Day 0. G-CSF-
mobilized PBSC (mean 5.0x106 CD34+ cells/kg) from DLA-
haploidentical donors were infused followed by posttransplant
immunosuppression with MMF (10 mg/kg BID SQ on Days 0-
40, 5 mg/kg BID SQ on Days 41-100) and CSP (15mg/kg BID
PO on Days -1 to 100). Leucocytes from CTLA4-Ig-treated
dogs were hyporesponsive to donor cells in mixed leukocyte
culture on Day 0 before TBI through more than Day 28; how-
ever, they were still able to react to third-party DLA-mis-
matched donor cells and ConA stimulation. Four of 6 CTLA4-
Ig-treated dogs achieved initial engraftment with mixed
chimerism ranging from 5-78% donor. However, all dogs lost
their donor graft (<16 weeks after transplant) with reconstitu-
tion of autologous hematopoiesis after discontinuation or dose-
reduction of MMF/CSP when PBMC of the recipients
regained activity against donor cells. Donor specific tolerance
was induced with in vivo co-administration of CTLA4-Ig and
haploidentical donor PBMC. Haploidentical stem cell engraft-
ment using NMSCT was facilitated by CTLA4-Ig-mediated
costimulatory blockade. Engraftment was lost after discontinua-
tion of MMF/CSP immunosuppression. Modifications to our
tolerance induction and immunosuppression protocols are
being tested to achieve longer lasting engraftment in the
absence of immunosuppression.
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A NEW METHOD FOR RAPID MOLECULAR GENOTYPING OF SINGLE
NUCLEOTIDE POLYMORPHISMS (SNP) ASSOCIATED WITH MINOR
HISTOCOMPATIBILITY ANTIGENS (MHA)
Miklos, D.; Hochberg, E.; Mattes-Ritz, A.; Guo, L.; Neuberg, D.;
Alyea, E.; Antin, J.; Soiffer, R.; Ritz, J. Dana-Farber Cancer Institute,
Boston, MA
Molecular typing of HLA Class I and Class II major histocom-
patibility antigens allows selection of optimal donors for unrelated
allogeneic hematopoietic stem cell transplantation (HSCT). Minor
histocompatibility antigens (mHA) are also known to inﬂuence out-
come following HSCT, but are not currently employed to select
potential donors. MHA are peptides derived from normal cellular
proteins that contain single amino acid polymorphisms presented
by MHC Class I or Class II molecules. These amino acid polymor-
phism are encoded by genomic SNP. Minor antigen disparity
occurs when a homozygote donor is paired with a recipient who
expresses at least one copy of the alternative mHA allele. Heterozy-
gote donors are tolerant of either allele. To identify patients with
mHA disparate donors we utilized Pyrosequencing™ which is a
rapid short-read quantitative sequencing technology based on the
detection of pyrophosphate release by DNA polymerase when a
nucleotide complementary to the evaluated strand is added. Using
Pyrosequencing we determined the allele frequency of SNP encod-
ing 5 mHA (HA-1, HA-2, HA-8, CD31 codons 125 and 563) in 75
normal donors. Disparity for these mHA was then determined in
30 patients and their HLA-identical related and unrelated donors.
Pyrosequencing rapidly identiﬁed pairs with mHA disparity. This
method is readily applicable to identiﬁcation of mHA disparity in
large cohorts of patients and may improve future donor selection.
IMMUNE RECONSTITUTION
23
GROWTH HORMONE ACCELERATES IMMUNE RECOVERY FOLLOWING
ALLOGENEIC BONE MARROW TRANSPLANTATION
Chen, B.J.; Cui, X.; Chao, N.J. Duke University Medical Center,
Durham, NC
In this study, we tested whether growth hormone could acceler-
ate the recovery of the immune system in an allogeneic bone mar-
row transplantation model since this hormone was demonstrated
to reverse T cell defects in Snell-Bagg dwarf mouse. Lethally irra-
diated BALB/c recipients (H2d) were transplanted with 5x106 of T
cell-depleted bone marrow cells from major histocompatibility
complex mismatched donor C57BL/6 mice (H2b). These animals
were followed for phenotypic immune recovery and the ability to
reject third-party grafts. Administration of human recombinant
growth hormone in the first 4 weeks significantly improved the
CD4+ T cell counts in peripheral blood on day +14 (44±14 vs.
33±7/µl blood, P<0.05) and day +21 (326±108 vs. 178±63/µl
blood, P<0.01) compared with the saline control. These differ-
ences were no longer signiﬁcant by day +28 in spite of continued
growth hormone administration. Similar effects were also
observed on CD8+ T cells and B220+ B cells. The improvements
in phenotypic T and B cell counts were at least partly from more
rapid regeneration of donor-derived immune cells as the numbers
of these cells increased after the treatment with growth hormone.
In order to determine whether the treatment with human recom-
binant growth hormone can also improve functional immune
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recovery, heart grafts from third-party (C3H/HeJ, H2k) neonates
were transplanted into the pinnae of ears of recipient mice subcu-
taneously on day +21 after bone marrow transplantation. As
demonstrated in the table, the bone marrow recipients treated
with growth hormone rejected the third-party grafts faster than
those treated with control saline (median survival time: 18.5 days
vs. 31 days). These data demonstrated that human recombinant
growth hormone can accelerate the immune reconstitution both
phenotypically and functionally following allogeneic bone marrow
transplantation.
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TREC EXPRESSION BY HUMAN CD4+ CD25+ T-CELL SUBSETS WITH
REGULATORY ACTIVITY
Woodliff, J.1; Johnson, B.1; Keever-Taylor, C.1; Douek, D.2; Truitt, R.1
1. Medical College of Wisconsin, Milwaukee, WI; 2. NIH Vaccine
Research Center, Bethesda, MD
Regulatory T-cells (Treg) suppress the alloreactivity of infused T-
cells in murine models of allogeneic BMT and donor leukocyte
infusion (DLI) (JI 163:6479-87, 1999). Although donor-BM-
derived, an intact host thymus was essential for Treg production. In
the absence of a functional thymus, DLI resulted in lethal GVHD.
Based on these data, we hypothesized that thymic function might
also inﬂuence the risk of GVHD after DLI therapy in human BMT
recipients. Thymopoietic activity can be assessed in humans by
measuring TCR-rearrangement excision circles (TREC) levels
using real-time PCR. “Recent thymic emigrant cells” generally
have high TREC levels. Functional studies showed regulatory
activity by CD4+CD25+ T-cells in allo-MLR cultures. We assessed
the TREC levels of putative CD4+CD25+ Treg-cells from normal
human PB and thymus tissue based on CD25 and CD45RO expres-
sion. The data are shown below as the mean TRECs per 105 CD4+
T-cells. As expected, thymic cells had higher TREC levels. TREC
levels in thymic CD25+ cells were high regardless of CD45RO
expression (ratio CD45RO+:CD45RO- = 1:1.25). In contrast,
CD25+CD45RO+ cells in the PB had lower TREC levels than
CD45RO- cells (ratio 1:14), suggesting cell division in the periph-
ery and dilution of TRECs among daughter cells. Studies assessing
thymopoiesis post-BMT showed that TREC levels in PB CD4+
and CD8+ T-cells inversely correlated with age and severity of
chronic GVHD. Future studies will determine if TREC expression
together with cell surface phenotype (CD4+CD25+CD45RO+/-)
identiﬁes a thymic-derived regulatory subpopulation similar to that
identiﬁed in the preclinical mouse model.
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RECOVERY OF CD8+ T CELL POPULATIONS POST TRANSPLANT
Hakim, F.T.; Memon, S.A.; Gress, R.E. National Cancer Institute,
Bethesda, MD
Transplant conditioning regimens in adults result in severe, pro-
longed depletion of T cells, which may limit responses to vaccines
and viral infections. By correlating results from flow cytometry,
thymic imaging, T cell receptor (TCR) rearrangement excision
circles (TREC) and BV TCR spectratyping, we have demonstrat-
ed that thymic recovery occurs in older adults and plays a central
role in the long term recovery of CD4+ T cell levels and TCR
repertoire diversity. We have now characterized CD8+ T cell
repopulation post autologous transplant, assessing the contribu-
tions of homeostatic expansion of mature cells and thymic-
dependent maturation. Increases in a CD28- subpopulation of
activated CD8+ T cells dominated early recovery in many adults,
but was not correlated with either thymic enlargement or increas-
es in frequency of TREC in total peripheral blood CD8+ T cells,
a functional measure of recent thymic emigrants. In contrast, the
protracted recovery of naïve CD4+ T cells (CD45RA+ CD62L+)
was correlated with recovery of naïve CD8+ T cells (defined
through TREC analysis of sorted subsets as CD28+ CD45RA+
CD11a(dull)). Moreover, the emergence of circulating T cells
containing TREC followed the same time course in both CD8+
and CD4+ T cells and the frequency of TREC in CD8+ T cells
correlated with that of CD4 cells. This study therefore demon-
strates that thymic function does recover in a subset of adults post
transplant, that the kinetics and the consequences of thymic
recovery are similar for both CD4+ and CD8+ T cells, and that
the RA/RO paradigm, that thymic-dependent repopulation may
be tracked by multi-parameter FACS analysis, can be extended to
CD8+ T cells. The return of thymic function provides evidence
for regulation of thymic activity in maintaining peripheral T cell
homeostasis. Characterization of such thymic regulation is critical
to the development of strategies to enhance thymic activity for
therapeutic purposes.
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THE THYMIC STROMAL GENE SPATIAL REGULATES THE SIZE OF
THYMOCYTE CELL POPULATIONS
Flomerfelt, F.A.; Gress, R. National Institutes of Health, National
Cancer Institute, Experimental Transplant Immunology, Bethesda, MD
Thymic stroma plays an indispensable role in thymopoiesis. How-
ever, the underlying molecular details regarding the interface between
stroma and developing thymocytes remains obscure. To study this
area, we cloned genes expressed in thymic stromal cells. One of these
genes, named Spatial, is alternatively spliced to generate 2 mRNAs in
mouse thymus and lymph node. A human homolog of Spatial is also
expressed in thymus. Both mRNAs encode proline rich proteins and
their closest amino acid homology is to homeobox and POU domain
transcription factors. Both forms of Spatial fused to the green ﬂuores-
cent protein (GFP) localize to the nucleus in transfected cells. Spatial
is not expressed in thymocytes, but it is expressed in alymphoid 2-
deoxyguanosine-treated day 14 fetal thymic organ culture (FTOC)
and in reaggregated FTOC. An antiserum raised against a C-terminal
peptide detected Spatial protein in subcapsular cells using frozen thy-
mus sections. In Spatial knockout mice, an increase in absolute thy-
mocyte numbers relative to wildtype littermates was seen as the mice
aged over 3-12 months. The most dramatic increase in cell number
was seen in the DN1 and DN2 stages that represent the earliest thy-
mocyte stages. In aged Spatial KO mice, the increase in thymus size is
correlated with a greater percentage of T cells with a naïve phenotype
in the periphery compared to wildtype littermates. No defects were
noted in either positive on negative selection using TCR transgenics
crossed to the Spatial KO. In Rag2 and Spatial double knockout mice
(DKO), a more dramatic increase in thymocyte cell numbers was
observed when compared to a Rag2 -/- mouse. These ﬁndings sug-
gest that Spatial may be involved in a stromal cell function that regu-
lates thymocyte population size and thymic output but does not dis-
rupt intrathymic quality control processes.
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IMMUNOLOGIC EFFECTS OF RECOMBINANT HUMAN GROWTH HOR-
MONE AFTER CONGENEIC BONE MARROW TRANSPLANTATION
(BMT) IN YOUNG VERSUS AGED MICE
Sun, R.1; Welniak, L.A.1; Murphy, W.J.2 1. LMI, NCI at Frederick,
Frederick, MD; 2. IRSP, SAIC-Frederick, Frederick, MD
Decline in circulating levels of growth hormone (GH) has been
associated with both age and loss of immune function. There is
strong evidence that GH improves lymph-hematopoietic recovery
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in young mice after syngeneic BMT. We therefore assessed the
effect of GH administration on lymphoid reconstitution after
BMT in aged mice. Aged (>12 months) and young (8 weeks)
CD45.2+ C57BL/6 mice received 900 cGy total body irradiation
followed by infusion of 1 million congeneic CD45.1+ BMC. After
the transplant, mice received 2.5mg rhGH/kg or vehicle control,
5x per week, for 3 weeks. Immunologic recovery was assessed at
days 21 and 28 post-BMT. Administration of rhGH resulted in
signiﬁcant increases in thymic and bone marrow cellularity at both
time-points in both treated age groups compared to age-matched
animals. Donor cell (CD45.1+) engraftment of the thymus was
significantly increased at day 21 in rhGH-treated animals. The
level of engraftment in aged mice was comparable to vehicle con-
trol treated young mice. Although the rhGH-treated young mice
continued to show enhanced donor cell repopulation of the thy-
mus over age-matched vehicle control treated animals, the beneﬁt
of rhGH treatment was lost with the cessation of treatment in the
old animals. However, this treatment still resulted in significant
increases in peripheral lymphoid engraftment at day 28 of both
splenic CD4+ and CD8+ T cells and corresponding rises in T cell
function as measured by ConA response from GH-treated aged
mice compared to age-matched vehicle-treated mice. B cell pro-
duction, as measured by B220+sIgM-cells and IgM+ B cells were
signiﬁcantly enhanced, as was B cell mitogen responses to LPS.
rhGH administration after congeneic BMT promoted multilin-
eage lymphopoietic reconstitution in aged mice and may be of
clinical use for accelerating immune reconstitution after autolo-
gous BMT. Funded in part by DHHS #NO1-CO-12400.
LATE EFFECTS/QUALITY OF LIFE
28
OPTIMISM AND THE OUTCOME OF HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Lee, S.J.2; Loberiza, F.R.1; Rizzo, D.1; Antin, J.H.2; Soiffer, R.J.2;
Weeks, J.C.2 1. Medical College of Wisconsin, Milwaukee, WI;
2. Dana-Farber Cancer Institute, Boston, MA
Context.—An optimistic attitude when facing a life-threaten-
ing medical condition is hypothesized to be beneficial. Howev-
er, the actual impact of optimism on outcome is controversial.
We hypothesized that any effect of optimism would be
enhanced and thus more detectable in patients undergoing
semi-elective, high-risk medical procedures. Hematopoietic
stem cell transplantation for hematologic malignancies is an
example of a procedure with significant morbidity and mortali-
ty risks usually performed with curative intent. Objective.—To
correlate patient-reported optimism prior to hematopoietic
stem cell transplantation with outcome following the proce-
dure Design.—Prospective cohort study with baseline and 6
month surveys enrolled July 1996 through November 1999
and follow-up to May 2001. Setting.—Tertiary care transplant
center in the United States Participants.—313 autologous and
allogeneic stem cell transplant patients with evaluable data
from the 458 baseline surveys mailed Main Outcome Mea-
sures.—Survival and quality of life as measured by the Short
Form 36, Quality of Life Index, and constructed questions
Results.—Optimism prior to transplantation correlated with
better mental and emotional functioning before transplanta-
tion and higher expectations for a successful transplant proce-
dure, but not with physical status or medical condition. Opti-
mists had better survival in the first 2 months after
transplantation (adjusted RR 0.45, 95% CI 0.22-0.92, p=0.03),
but by 6 months survival and quality of life were indistinguish-
able between optimistic and less optimistic patients. Conclu-
sions.—Our data do not support a role for optimism in deter-
mining the long-term outcome of hematopoietic stem cell
transplantation.
LEUKEMIA
29
A HIGH CD34 CELL DOSE IS ASSOCIATED WITH AN IMPROVED
LEUKEMIA-FREE SURVIVAL IN RECIPIENTS OF HLA-IDENTICAL BONE
MARROW OR PERIPHERAL BLOOD STEM CELLS
Ringden, O.1; Barrett, J.2; Zhang, M.3; Loberiza, F.3;
Horowitz, M.M.3 1. Karolinska Institutet, Stockholm, Sweden;
2. National Institutes of Health, Bethesda, MD; 3. International Bone
Marrow Transplant Registry, Milwaukee, WI
We studied the association between CD34 cell dose and out-
come in 359 recipients of bone marrow (BM) and 511 recipients
of peripheral blood stem cells (PBSC) from HLA-identical sib-
lings for leukemia, reported to the IBMTR and transplanted
between 1995 and 1998. The patients were divided into those
receiving low or high dose, below or above the median, for BM
(<3 x 10E6/kg) and PBSC (<6 x 10E6/kg). The Cox proportional
hazard’s regression model was used to adjust for differences in
baseline characteristics of the patients, such as disease (AML,
ALL, CML), age, donor-patient CMV status, conditioning and
year of transplant. Multivariate analysis in the recipients of BM
showed that a high CD34 cell dose was associated with time to
untransfused platelets >20 x 10E9/l (RR 1.29, p=0.042), trans-
plant-related mortality (RR 0.64, p=0.065), leukemia-free survival
(LFS) (RR 0.63, p=0.006) and survival (RR 0.74, p=0.081). Among
the recipients of PBSC, a high CD34 dose was associated with
time to ANC >0.5 x 10E9/l (RR 1.37, p<0.001) and platelets >20 x
10E9/l (RR 1.34, p=0.003), chronic GVHD (RR 0.36, p=0.009),
relapse (RR 0.62, p=0.029) and LFS (RR 0.74, p=0.03). Other fac-
tors of importance for LFS in BM recipients included disease
stage (p<0.001), Karnowsky score at transplant (p=0.018) and
WBC at diagnosis (p=0.007). For PBSC recipients, disease-stage
(p<0.001) and ALL (p=0.01) or CML (p=0.004) vs. ALL were also
significant. To conclude, a high (above the median) CD34 cell
dose was associated with an improved LFS in recipients of BM as
well as PBSC in multivariate analysis.
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UNRELATED DONOR BONE MARROW TRANSPLANT (URD BMT) FOR
PEDIATRIC PATIENTS WITH MYELODYSPLASIA (MDS) AND ACUTE
MYELOID LEUKEMIA (AML)
Bunin, N.1; Abella, E.2; Orchard, P.3; Haagenson, M.4; King, R.4
1. Children’s Hospital of Philadelphia, Philadelphia, PA; 2. Karmanos
Cancer Institute, Detroit, MI; 3. University of Minnesota, Minneapolis,
MN; 4. National Marrow Donor Program, Minneapolis, MN
The clinical features which inﬂuence outcome for URD BMT for
pediatric patients (pts) with AML/MDS have not been well
defined. This study reviewed the outcomes of 507 pts <21 years
who received URD BMT from 1988 to 2001 to deﬁne these prog-
nostic factors. Pts had de novo AML/MDS, and no preceding
BMT. Disease stages included: CR1:20%, CR2: 36%, CR3:3%,
CR4:1%, primary induction failure: 14%, relapse 1:17%, relapse
2:9%, unknown:<1%. Recipient ages included: <5 yrs:34%, 6-10
yrs: 15%, 11-17 yrs:35%, 18-21 yrs: 16%. Marrow was serological-
ly matched at A, B and allele matched at DRB1 in 58%, serologi-
cally matched at A, B and potential DR matched in 9%, and mis-
matched in 33% of pts. Marrow was T cell depleted for 39%, and
conditioning included total body irradiation for 85% of pts. Prog-
nostic factors, including age at BMT, FAB, duration of CR1, HLA
matching and T cell depletion (TCD) were analyzed using both
univariate and multivariate analyses. DFS was inferior for patients
beyond CR2, or in relapse (39% vs 18%, p<.0001). Pts >CR2, or in
relapse had higher overall non relapse mortality (NRM) (p=0.03).
Relapses occurred in 32%, with 18% in the CR1, CR2 pts and 50%
for CR3/relapse (p<.0001). Grades III-IV GVHD occurred in 30%
of pts, and was less common in pts who received DRB1 matched
grafts (24% vs 37%, p=0.01). Chronic GVHD occurred in 34% of
pts, with no difference between HLA matched or mismatched
recipients. Although TCD did not affect DFS or NRM, severe (III-
IV) GVHD was less common (23% vs 33%, p=0.02), as was chron-
ic GVHD (23% vs 41%, p<.0001). Chemotherapy only condition-
ing was associated with improved DFS of 46% vs 31% for TBI
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recipients (p=0.02). URD BMT may be curative therapy for many
children with AML/MDS, particularly in early disease stages.
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CML28 AND CML66 ARE GVL-ASSOCIATED ANTIGENS THAT ARE
OVEREXPRESSED IN MALIGNANT HEMATOPOIETIC TISSUE
Wu, C.J.1; Yang, X.2; Chen, L.1; Alyea, E.P.1; Soiffer, R.J.1;
Dranoff, G.1; Ritz, J.1 1. Center for Hematologic Oncology, Dana-Far-
ber Cancer Institute, Boston, MA; 2. Department of Medicine, Baylor
College of Medicine, Houston, TX
Donor lymphocyte infusion (DLI) reliably induces durable
remission in 75-80% of patients with relapsed CML following
bone marrow transplantation. To identify targets of the graft-ver-
sus-leukemia effect of DLI, we used CML DLI responder sera to
screen a CML cDNA expression library. Two of the identified
targets were derived from genes encoding proteins of 66 kD
(CML66) and 28 kD (CML28). The development of high titer
specific IgG responses against both antigens in DLI responders
correlated with immune-induced remission. CML66 has no
known homologies, and its coding region contains no known
functional motifs. CML28 is identical to hRrp46p, a component
of the human exosome, which is involved in the 3’ processing of
RNA. The human exosome contains known auto-antigens, such as
PM/Scl-100, an autoantibody target of patients with polymyositis
or scleroderma. Analysis of CML66 and CML28 expression
revealed striking similarities. Northern blots showed high-level
expression in a variety of leukemia and epithelial cell lines, but not
in normal tissue, except for testis. Recombinant CML66 and
CML28 were used to generate monoclonal antibodies. By western
blot, endogenous CML28 localized to predominantly nuclear
fractions of K562 cells, whereas endogenous CML66 localized
primarily in the cytoplasm. Western blotting against whole cell
lysates derived from patient cells revealed high-level expression in
CLL, ALL, AML, and CML patients, compared to low-level or
absent expression in normal bone marrow or peripheral blood.
However, humoral immunity against these antigens was only
detected in sera from some patients who had undergone immune-
based therapy (DLI or IFN-alfa), but not in untreated patients, or
patients treated with non-immune therapy. The similar expression
patterns of CML28 and CML66 suggest that overexpression may
be common to antigens that are targeted by the humoral immune
response following DLI. In conjunction with overexpression, our
results suggest that immune-based therapies can break “tolerance”
to these antigens.
LYMPHOMA/MULTIPLE MYELOMA
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PRELIMINARY RESULTS FROM A PHASE I/II STUDY OF 153-SAMARI-
UM EDTMP (153-SM-EDMTP) WITH FIXED DOSE MELPHALAN
PERIPHERAL STEM CELL TRANSPLANTATION (PBSCT) FOR MULTI-
PLE MYELOMA (MM)
Dispenzieri, A.; Wiseman, G.A.; Lacy, M.Q.; Litzow, M.R.;
Tefferi, A.; Inwards, D.J.; Micallef, I.N.; Gastineau, D.A.; Ansell, S.;
Gertz, M.A. Mayo Clinic, Rochester, MN
Background: High dose chemoradiotherapy prolongs the
remission and survival of patients with myeloma (MM). 153-
SmEDTMP is a therapeutic radioisotope linked to a diphospho-
nate compound that binds tightly to bone. It has a short range
beta emission with a 1.9 day half-life and rapid clearance from
non-osseous tissues. Methods: MM patients who were candidates
for autologous PBSCT were eligible. For the phase I portion of
the trial, patients are treated with a ﬁxed dose of melphalan (200
mg/m2) and an escalating dose of the 153-SmEDTMP. The orig-
inal four dose levels were 6, 12, 19.8, and 30 mCi/kg. Because of
variability of bone localization of 153-SmEDTMP noted after the
ﬁrst 12 patients, the protocol was modiﬁed to include a trace dose
of 153-SmEDTMP with a 24-hour whole body uptake measure-
ment. For the subsequent 6 Phase I patients and all Phase II
patients, the 153-SmEDTMP dose was fixed with a target red
marrow dose of 4000 cGy. Melphalan was given (Day –1).
Results: Nineteen patients have been treated. Median age at
PBSCT was 58, range 43-74. Two patients were primary refracto-
ry, 11 primary responsive, 1 refractory relapse, and 7 in untreated
relapse. Seven and four patients, respectively, had a PCLI >= 1
and a B2M > 2.7 prior to PBSC mobilization/transplant. No dose
limiting toxicity nor cases of TTP have been observed during the
14 months median follow-up. At the highest dose level, median
times to ANC > 0.5 and platelet > 20 were 13 and 12 days, respec-
tively. All patients have engrafted. Of the 14 evaluable patients,
the overall response rate is 93% including 7 VGPR and 4 CR.
Conclusions: Addition of 153-Sm EDTMP to the Melphalan
conditioning appears to be safe and well tolerated. The additional
beneﬁt is not known but the ORR and CR rates are promising.
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HIGH COMPLETE REMISSION RATE OF DOSE_REDUCED ALLOGRAFT
TO INDUCE GRAFT VERSUS MYELOMA EFFECT AFTER CYTOREDUC-
TIVE AUTOTRANSPLANT IN MULTIPLE MYELOMA
Kröger, N.1; Schwerdtfeger, R.2; Kiehl, M.4; Sayer, H.3; Renges, H.1;
Zabelina, T.1; Fehse, B.1; Wittkowsky, G.5; Kuse, R.5; Zander, A.1
1. University Hospital, Hamburg, Germany; 2. Deutsche Klinik, Wies-
baden, Germany; 3. University Hospital, Jena, Germany; 4. Bone Mar-
row Transplantation, Idar Oberstein, Germany; 5. Hematology St
Georg, Hamburg, Germany
Purpose: To evaluate the toxicity, engraftment, chimerism, acute
graft-versus host disease (GvHD) and response of a dose-reduced
allograft after cytoreductive autograft for patients with multiple
myeloma (MM) . Patients and Methods: 14 patients with advanced
stage II/III MM first received autografting after melphalan (200
mg/m2) followed by a dose-reduced regimen consisting of ﬂudara-
bine (180 mg/m2), melphalan (100 mg/m2), ATG (3x10mg/kg) and
allografting from related (n=7) or unrelated n=7) donors to induce
a graft versus myeloma effect. The median interval between autol-
ogous and allogeneic transplantation was 119 days (range 60-210).
Results: After dose-reduced allografting all patients became neu-
tropenic ( < 0.2 x109/L) and required platelet transfusions. No
graft failure was observed. The median time for leukocyte (>1 x
109/L) and platelet (>20 x 109/L) engraftment was 16 (range 13-
22) and 24 days (range 14-43), respectively. Complete donor
chimerism was detected in all patients after a median of 30 days
(range 19 – 38)post allografting. Acute GvHD occured in 4
patients (30%). Severe grade III GvHD was observed in two
patients (15%). Two of nine evaluable patients developed chronic
GvHD (22%). Grade II toxicity was primarily mucositis (50%) and
liver toxicity (42%). One patient died with multiorgan failure after
septicemia and pneumonia on day 22 after allogeneic transplanta-
tion. Overall transplant related mortality at day +100 was 7%. 70%
achieved a complete remission (CR) with negative immunoﬁxation
and 4 patients have PR with still decreasing monoclonal bands.
Conclusion: The tandem auto-allo-transplant-protocol provides
rapid engraftment with complete donor chimerism, managable
toxicity and low day +100 treatment related mortality. The high
rate of CR is encouraging but a longer follow-up is needed to
determine late mortality and late relapse.
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TANDEM AUTOLOGOUS STEM CELLS TRANSPLANTATION OR ON
DEMAND SECOND TRANSPLANTATION IN PATIENTS WITH MULTIPLE
MYELOMA?
Elice, F.; Piccin, A.; Tosetto, A.; Sartori, R.; Miggiano, C.;
Raimondi, R.; Rodeghiero, F. San Bortolo Hospital, Vicenza, Italy
Between August 1993 and May 2000, 96 symptomatic patients
were enrolled in a high-dose program with autologous stem cell
transplantation (auto-SCT): median age 57 years (range 36-68),
M: 50, F: 46; M-component type: IgG 55%, IgA 13%, IgD 4%,
light chain 24%, non secretory 4%; stage I: 19%, II: 35%; III:
46%, stage B: 11%. CD34+ cells (PSC) were collected after
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debulking with 2-4 VAD courses plus high dose cyclophos-
phamide. 80/96 patients, in permitting clinical conditions and
with sufﬁcient number of PSC, actually underwent auto-SCT with
melphalan 200 mg/m2. In 19 patients a second auto-SCT was per-
formed on demand in relapsed or progressive disease. The median
follow-up was 29 months (range 3-71,7) from the ﬁrst auto-SCT.
The median overall survival (OS) has not yet been reached (OS at
60 months was 76%) and the median event-free survival (EFS) was
18 months. The median OS from second salvage auto-SCT was
25 months and the median EFS was 9,7 months. The maximum
response (defined using the ABMTR criteria) attained after the
ﬁrst auto-SCT was: complete remission (CR) 21%, partial remis-
sion (PR) 68%, minimal response (MR) 4%; after salvage auto-
SCT it was: CR 7%, PR 57%, MR 21%. The early transplant
related mortality (within 60 days) after the first auto-SCT was
2,5%, no deaths occured after the second auto-SCT. The inci-
dence of blood product transfusions and non haematological
severe toxicities showed no statistically significant differences
between the ﬁrst and the second auto-SCT. Our data show that a
second salvage transplantation is safe and effective in prolonging
the survival of myeloma patients. Notwithstanding the method-
ological limitations of an indirect comparison, the OS obtained
with a single auto-SCT and second salvage auto-SCT on demand
was apparently longer than the OS reported in other studies with
tandem transplantation (Barlogie, 1999). Pending the ﬁnal results
of randomized trials (Attal, 2000), our ﬁndings raise the question
of the most appropriate timing for a second transplantation.
SOLID TUMORS
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SALVAGE TREATMENT WITH HIGH-DOSE CHEMOTHERAPY FOL-
LOWED BY HEMATOPOIETIC STEM CELL SUPPORT IN GERM CELL
TUMOR PATIENTS
Rosti, G.1; De Giorgi, U.1; Salvioni, R.2; Papiani, G.1; Monti, M.1;
Pizzocaro, G.2; Marangolo, M.1 1. General Hospital, Ravenna, Italy;
2. National Cancer Institute, Milan, Italy
High-dose chemotherapy (HDCT) followed by hematopoiet-
ic stem cell support (HSCS) can be potentially curative in
patients with germ cell tumor (GCT) who relapse or who have
an inadequate response after standard-dose chemotherapy. We
report our experience with HDCT as salvage therapy in GCT
patients. Between 1986 and 2000, at the Department of Oncol-
ogy in Ravenna, in cooperation with the Urologic Unit of the
National Cancer Institute of Milan, 84 GCT patients (77 M, 7
F), median age 29 years, received 105 courses of HDCT with
HSCS as salvage treatment. HDCT consisted of CE (carbo-
platin, etoposide) regimen in 26 courses, ICE (ifosfamide, car-
boplatin, etoposide) in 44 courses, and CarboPEC (carboplatin,
etoposide, cyclophosphamide) in 35 courses. Totally, 75 cours-
es were supported by bone marrow transplantation, 29 by
peripheral blood stem cells, and one by both of them. All
patients were stratified as good, intermediate, and poor risk
categories according to a validated prognostic index (Beyer et
al 1996). Overall, 28 (33%) patients are continuously disease-
free. In the good risk group, 24 patients (69%) are continuous-
ly disease-free, compared with 4 (13%) in the intermediate risk
group (P < .001), and no one in poor risk group (P < .001).
Treatment-related mortality occurred only in the poor risk (n =
6), and intermediate risk groups (n = 4). In our experience,
HDCT induced impressive long-term remissions as salvage
treatment in good risk patients. Moreover, use of validate
prognostic classifications may contribute to better define the
role of HDCT besides improving the outcome of patients with
GCT. The definitive statement on the possible role of HDCT
in GCT will derive from the ongoing phase III randomized
studies.
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THE CXCR4–SDF-1 AXIS REGULATES METASTATIC RHABDOMYOSAR-
COMA CELL BEHAVIOR
Ratajczak, M.Z.1; Libura, J.1; Justyna, D.1; Marcin, M.1; Janowska-
Wieczorek, A.2 1. James Graham Brown Cancer Center, Louisville,
KY; 2. Department of Medicine, Edmonton, AB, Canada
We hypothesized that the CXC chemokine receptor-4
(CXCR4)–stromal-derived factor-1 (SDF-1) axis may be involved
in metastasis of CXCR4-positive tumor cells into the bone mar-
row and lymph nodes, which secrete the chemokine SDF-1. To
explore this further we phenotyped various human tumor cell lines
for expression of CXCR4 and found to our surprise that it was not
detectable (as assessed by FACS) on human melanoma (10), breast
(7) and lung cancer (5) cell lines, but was highly expressed on the
cell surface in 7 out of 10 rhabdomyosarcoma (RMS) cell lines (as
determined by FACS) and in 10 out of 10 RMS cell lines (as
assessed by intracellular staining). We also found that the more
metastatic alveolar RMS cell lines expressed higher levels of
CXCR4 than the embryonal RMS ones. Since RMS frequently
metastasizes to the bone marrow and lymph nodes we postulated
that the CXCR4–SDF-1 axis could play an important role in this
process. Hence we tested various biological responses of CXCR4+
RMS cell lines to stimulation by SDF-1 such as phosphorylation
of signaling proteins, proliferation, survival, migration and adhe-
sion as well as expression of matrix metalloproteinases (MMPs)
and their inhibitors (TIMPs). We found that, although SDF-1 did
not affect proliferation or survival of these cell lines, it induced in
several of them i) phosphorylation of MAPK p42/44, ii) locomo-
tion, iii) chemotaxis across membranes covered by laminin or
fibronectin, iv) adhesion to laminin and fibronectin, and v)
increased MMP-2 and diminished TIMP secretion. Based on
these observations we suggest that the CXCR4–SDF-1 axis may
play an important role in tumor spread and metastasis of RMS
cells to bone, and that molecular strategies aimed at inhibiting this
axis may thus prove to be useful therapeutic measures.
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LONG FOLLOW-UP OF PATIENTS WITH PRIMARY BREAST CANCER
AND ≥ 10 INVOLVED AXILLARY LYMPH NODES AFTER HIGH-DOSE
CHEMOTHERAPY AND AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANT
Damon, L.E.1; Wolf, J.L.2; Rugo, H.S.1; Gold, E.O.2; Cassidy, M.2;
Irwin, D.H.2; Cecchi, G.R.2; Tracy, M.A.2; Cohen, N.2; Linker, C.A.1
1. University of California, San Francisco, San Francisco, CA; 2. Alta
Bates Cancer Center, Berkeley, CA
80 patients with primary breast cancer and ≥10 involved axillary
lymph nodes were treated with conventional-dose adjuvant
chemotherapy followed by high-dose chemotherapy (CTM) and
autologous hematopoietic stem cell transplant (HSCT). CTM
consisted of cyclophosphamide 6 g/m2, thiotepa 600 mg/m2, and
mitoxantrone 24-40 mg/m2. All patients received standard chest
wall radiation 6-8 weeks after HSCT and hormone receptor-posi-
tive patients also received 5 years of tamoxifen. The median num-
ber of involved axillary lymph nodes was 14.5 (10-40). There were
3 (3.8%) treatment-related deaths. With a median follow-up of
survivors of 6.9 years (2.5-10.4), the 5-year, 7-year, and 10-year
event-free survivals (EFS) were 60±11,53 ±12, and 45±17%,
respectively. The 5 year, 7 year, and 10 year overall survivals (OS)
were 68±10, 65 ±11, and 59±13%, respectively. The median EFS
is 5.2 years. The median OS has not been reached. The OS is bet-
ter for hormone receptor-positive patients than receptor-negative
patients (p=0.04; relative risk, 2.1). There was no signiﬁcant dif-
ference in disease-free survival comparing hormone receptor-posi-
tive patients to receptor-negative patients. We conclude that
CTM with autologous HSCT produces excellent outcomes in pri-
mary breast cancer patients with ≥10 involved axillary lymph
nodes. Very few events occur after 7 years from treatment. The
results of prospective, randomized trials of high-dose chemothera-
py and HSCT versus conventional-dose chemotherapy are still
pending but should answer whether high-dose chemotherapy and
HSCT is better than conventional-dose chemotherapy in this
group of poor-risk breast cancer patients.
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CHIMERISM AND TOLERANCE FOLLOWING IN UTERO TRANS-
PLANTATION WITH EMBRYONIC, FETAL AND ADULT SOURCES OF
STEM CELLS
Carrier, E. University of CA, San Diego, La Jolla, CA
In utero stem cell transplantation is a novel strategy that may
lead to the development of non-toxic approaches for the
treatment of congenital disorders. We hypothesized that
robust fetal hematopoiesis and immune barriers prevent
development of a high degree of chimerism, necessary for the
correction of underlying disorders. In order to overcome
these barriers different sources of stem cells (embryonic, fetal
and adult, as well as cytokine stimulated) were used. We
found that fetal liver cells can engraft at > 1% in C57Bl/6à→
Balb/c donor/recipient combination, which is I-E+/I-E- and
non-permissive for engraftment. This level of chimerism was
associated with induction of tolerance as tested by skin graft
acceptance and a positive response to postnatal boosts (Carri-
er et al. Blood, 1995). This response was not seen when
adult bone marrow cells were used as a source of stem cells,
indicating that donor/recipient ontogenic compatibility plays
a role (Carrier et al. Transplantation 1997). To reproduce
clinical situation in which cytokine stimulated stem cells are
used, we have injected cytokine stimulated Sca+/Lin- cells
from the peripheral blood after in vivo recruitment with
SCF/GCSF. In vitro and in vivo assays demonstrated evidence
of allosensitization, supported by less optimal responses to
postnatal boosts (Carrier et al. J Lab and Clin Med 2000,
Donahue et al, Transplantation 2000). In order to clarify
the balance of tolerance vs immunity in prenatal transplanta-
tion, plasmid encoding Th2 determinant was injected prena-
tally. Upon postnatal re-exposure to plasmid specific protein,
brisk T cell memory responses were observed. These experi-
ments show that in utero administration of plasmid DNA
primes mice for a CD4 T cell response. These new data sug-
gests that tolerance or immunity may develop depending on
the conditions of prenatal transplant. This is a new hypothesis
that must be thoroughly tested before human prenatal proto-
cols can be applied.
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DONOR HEMATOPOIETIC CELLS EXPRESSING GREEN FLUORESCENT
PROTEIN (GFP) ARE SELECTIVELY LOST IN IMMUNOCOMPETENT
UNCONDITIONED MURINE RECIPIENTS
Bubnic, S.J.2,4; Nagy, A.3,4; Keating, A.1,4 1. Princess Margaret Hospi-
tal/Ontario Cancer Institute, Toronto, ON, Canada; 2. Toronto Gener-
al Research Institute, Toronto, ON, Canada; 3. Samuel Lunenfeld
Research Institute, Mount Sinai Hospital, Toronto, ON, Canada;
4. University of Toronto, Toronto, ON, Canada
While some studies suggest the utility of GFP for studying
hematopoiesis and transplantation, recent in vitro data indi-
cate that GFP may be immunogenic, raising concerns about
its value as a cell marker. To better address this, we used a
sex-mismatch murine transplant model with 20x106 male
donor cells infused into unconditioned female Balb/cByJ
recipients. Groups of mice were infused with marrow from: a)
transgenic GFP(+) mice crossed onto a Balb/cByJ background
for 8 generations, b) GFP(-) littermates which shared the
same strain background, or c) wild-type Balb/cByJ mice.
Donor cells were detected in the blood and marrow by FISH
using a Y chromosome paint and by flow cytometry for GFP.
Frequencies of donor cells in blood and marrow of uncondi-
tioned recipients were compared for these three transplant
groups. A control group underwent a conventional myeloabla-
tive transplant (8 Gy) with GFP(+) marrow. Frequencies of
circulating male donor cells at 1 week after transplant into
unconditioned recipients were similar by FISH: a) 1.2±0.7%,
b) 1.4±0.3%, c) 1.2±0.2%. GFP(+) cells were detected in
recipients of GFP(+) marrow at 1 week (1.5±0.2%), but no
GFP(+) cells were evident at later timepoints. Moreover, mar-
rows of recipients infused with male GFP(+) cells contained
no GFP(+) or FISH (+) cells 5 weeks after transplant, while
recipients receiving GFP(-) or wild type male cells had
2.5±2.1% and 3.8±0.3% donor cells, respectively, by FISH.
High levels of donor chimerism were evident in marrows of
transplant controls by flow cytometry and FISH, indicating
sustained engraftment of GFP(+) cells after myeloablation.
These data indicate that GFP is immunogenic in vivo and
cannot serve as a reliable cell marker in immunocompetent
mice. The time course suggests that the GFP(+) donor cells
were rejected by the recipients. Our studies also infer that
GFP should be avoided in human cell marking/tracking pro-
tocols involving immunocompetent individuals.
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AFTER OSTEOGENIC STIMULATION ADHESION MOLECULE EXPRES-
SION OF NONHEMATOPOIETIC PROGENITOR CELLS ISOLATED FROM
CORD BLOOD MIRRORS THAT OF MARROW DERIVED MESENCHYMAL
STEM CELLS
Goodwin, H.S.1; Quinn, C.O.2; Wall, D.A.1 1. Texas Transplant Insti-
tute, San Antonio, TX; 2. Washington University, St. Louis, MO
Cord blood (CB) contains a small population of nonhematopoietic
progenitors(NHP). We have previously reported that these adherent
cells acquire features of bone (alkaline phosphatase/hydroxyapatite
nodules/calcium flux) after exposure to osteogenic factors. After
exposure to the neurogenic factors (EGF/bFGF), they coexpress
neurospeciﬁc antigens (B-tubulin-III/glial ﬁbrillary acidic protein).
NHPs from CB and mesenchymal stem cells(MSCs) from BM have
similar antigen expression. Both lack expression of hematopoietic
differentiation antigens(CD34,CD45,CD14,CD2,CD3,CD15,
CD16,CD19,CD24,CD33,CD38,GlyA). Additionally, both NHPs
and MSCs express CD13+,CD29+ and CD44+. However, CB-
NHPs in our standard cultures (DMEM-LG,10% FBS) stained less
intensely than MSCs with antibodies to the adhesion molecules
CD105(SH2) and CD166(ALCAM), which are deﬁning markers of
this population. We hypothesized that CB-NHPs might represent a
more immature population compared to marrow MSCs. To examine
the inducibility of antigen expression, CB-NHPs were cultured in
our standard media with the addition of osteogenic factors(B-glyc-
erol phosphate/ascorbic acid/dexamethasone) or with neurogenic
factors(EGF/bFGF). The cells were exposed to differentiation media
for 7-days and then analyzed by ﬂow cytometry for changes in anti-
gen expression. With the addition of osteogenic factors, antigen
expression by CB-NHPs mirrored that of BM-MSCs in standard
media;the CB-NHPs that were only dimly positive for
CD90,CD105 and CD166 in our standard culture media showed a
signiﬁcant increase in expression of the three markers that deﬁned
their original difference from marrow MSCs. CB-NHPs after cul-
ture with neurogenic factors coexpressed neuro-speciﬁc markers (B-
tubulin III/GFAP),however no change in adhesion molecule expres-
sion was observed. Thus CB-NHP adhesion molecule expression can
be induced with osteogenic cytokine culture. Additional studies are
needed to understand if this is a distinct, primitive cell population.
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LINEAR POLYAMINE COPPER CHELATORS EXTEND LONG-TERM
CD34+ CELL EXPANSION
Peled, T.1; Treves, A.1; Nagler, A.2; Fibach, E.3 1. Gamida-Cell,
Jerusalem, Israel; 2. Sheba Medical Center, Tel Hashomer, Israel;
3. Hadassah Medical Center, Jerusalem, Israel
Self-renewal of hematopoietic stem/progenitor cells in cultures is
limited. We have found that synthetic linear polyamines extend the
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long-term expansion of cultures initiated with cord blood derived
CD34+ or CD34+Lin- cells in the presence of a combination of
four cytokines (Flt3, IL-6, TPO and SCF or IL-3). Extension of the
cultures was determined by measuring total cell proliferation, long
term CFU and numbers of CD34+ cells as measured following
affinity re-purification. This phenomenon persisted during the
long-term cultures even if the polyamine was present in the cultures
for only the ﬁrst three weeks. After three weeks in culture, there
was no difference in the total cells, CD34+ cells and CFU numbers.
However, in cultures exposed to the polyamine chelator for only the
ﬁrst three weeks, the numbers of CD34+ cells after eight weeks
were 10 fold higher as compared to control. The overall expansion
of CD34+ cells was 400 folds. These results indicated that the
chelator increases self-renewal potential during the early phase of
the culture (3 weeks), at a time where no difference in CFU, cells
and CD34+ cell numbers could be observed. We further demon-
strated that the biological activity of the synthetic linear polyamines
is related to their copper binding chemical properties. In this con-
text, substitution of the hydrogen with a methyl group at the copper
binding sites, diminished copper binding ability as well as the bio-
logical activity of the molecule. This novel method of extension of
self-renewal potential of stem/progenitor cells in short term cul-
tures can be utilized for improving engraftment of cord blood, in
which the numbers of cells is not sufﬁcient. Further studies of the
molecular events during the short-term exposure will help in better
controlling self-renewal and differentiation in ex-vivo conditions.
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EX VIVO EXPANSION OF CORD BLOOD CD34+ STEM CELLS: MAIN-
TAINING THE LONG-TERM ENGRAFTING ABILITY FOR ADULT
TRANSPLANTATION
Zhang, J.1; Nett, A.1; Heye, M.1; Brown, R.2; Burke, C.1; Welhausen, S.1;
Qiu, l.1; Herzig, R.H.1 1. University of louisville, Brown Cancer Center,
louisville, KY; 2. Quality Biological, Inc., Gaithersburg, MD
Umbilical cord blood(UCB)is an attractive alternative to marrow
or peripheral blood as a source of transplantable hematopoietic
cells. Given the limited stem cell content,ex vivo expansion would
potentially beneﬁt its use for adult patients.The focus of the pres-
ent studies is to define ex vivo conditions that enable optimal
expansion of hematopoietic cells for clinical application.We evalu-
ated expanded CD34+ UCB cells to indirectly determine whether
ex vivo expanded UCB cells maintain long-term repopulating
potential capability.Initial puriﬁed CD34+ cells from frozen UCB
collection were cultured in a deﬁned serum-free medium(QBSF-
60)with a combination of cytokines(stem cell factor,SCF;ﬂt-3lig-
and;thrombopoeitin,TPO).Fresh media with cytokines was supple-
mented or exchanged at day4,7,and10.CD34+ cells were
re-selected from expanded cell products on day7 and day14 and
were re-expanded for another 14days under the same conditions.
The clonogenic efﬁciency,CD34+ sub-populations and the expan-
sion potential were evaluated on day7,day10 and day14 by evaluat-
ing the following parameters:clonogenic progenitors(CFU-GM,
BFU-E,CFU-GEMM and HPP-CFC),long-term culture(LTC-
IC/105),and immunophenotypes(CD34+ cells and CD34+ sub-
populations).Simultaneously numerical expansion of various
stem/progenitor cells,including very primitive CD34+CD38-
HLA-DR- subpopulation and LTC-IC,clonogenic progenitors to
mature nucleated cells,were continually observed during the cul-
ture.After either 7days or 14days of expansion,reselection and fur-
ther culturing resulted in further expansion.The CD34+ cell
recovery after reselection was comparable after 7(62%)or 14days
(66%).There was continued expansion after reselection in both
groups with better fold-expansion in the cells reselected after 7
and 14days culture.CD34+ cells reselected after 7days of expansion
an expanded for 14 more days(group1)were compared to CD34+
cells reselected after 14days of expansion and expanded for 7 more
days(group2),a 21day expansion for both groups.In group1,the
CD34+CD38-DR- cells had 266-fold cumulative expansion,HPP-
CFU had 218-fold cumulative expansion and LTC-IC had 137-
fold cumulative expansion.By comparison,in group2,there was an
87-fold expansion of CD34+CD38-DR- cells,a 460-fold expansion
of HPP-CFU,and an 82-fold expansion of LTC-IC.These results
suggest that group1 would provide better approach and would
provide an UCB product suitable for adults.
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CHARACTERIZATION AND SHORT-TERM IN VIVO TRANSFER OF
EMBRYONIC NEURAL STEM CELLS
Mammolenti, M.M.; Torruellas, J.; Gajavelli, S.; Pantelis, T.; Levy, R.
University of Miami School of Medicine, Miami, FL
We are interested in developing strategies to examine
embryonic neural stem cells (NSC) in progenitor cell trans-
plant models. Cells were explanted and cultured from the cor-
tex of the brains of day 13 embryonic (E13) B6 mice and
grown in serum-free media with basic fibroblast growth factor
to select for neural stem cells (N2 media). Following a brief
culture period as a monolayer, cells were maintained as neu-
rospheres starting at passage one (P-1) in N2 media. Charac-
terization of P-2/3 cultures showed marginal levels of MHC
H-2K and H-2D class I and H-2 IA class II expression. How-
ever, these products could be strongly upregulated following
addition of ≥3 ng/ml mrIFNγ for 60 hours. To track and assess
the survival of these cells under transplant conditions, short
term in vivo experiments were initiated using neurospheres
generated from B6-GFP transgenic mice. Cells were implant-
ed into the peritoneal cavity or directly injected into the bone
marrow cavity of individual 7.5-8.5 Gy TBI syngeneic B6
hosts. 7AAD was used to determine whether cells were viable,
i.e. GFP+7AAD-, readily distinguishing the implanted cells
from host cells using flow cytometric analysis. Two hours fol-
lowing i.p. injection, mice were sacrificed and cells examined
from the peritoneal exudate (PE) and other compartments.
Live NSC were detected in the PE. Reculturing these cells in
N2 media after explant resulted in neurosphere growth (i.e.
GFP+) within one week. Interestingly, 3 hours following intra-
bone (i.e. tibia) injection, viable NSC progenitors were also
identified in this compartment by their ability to generate neu-
rospheres upon subsequent reculture ex-vivo. In summary,
these observations indicated that cells from ≥P4 NSC cultures
could survive and maintain their ability to form neurospheres
after a short time period in irradiated hosts.
SUPPORTIVE CARE
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DONOR LYMPHOCYTE INFUSIONS (DLI) IN PEDIATRIC PATIENTS
WITH NON-MALIGNANT DISEASES (NMD) FOLLOWING BLOOD AND
MARROW TRANSPLANTATION (BMT)
Loechelt, B.J.; Sande, J.; Boyer, M.; Filipovich, A.H.; Harris, R.;
Thomson, B.; Smith, F.O.; Gross, T.G. Children’s Hospital Medical
Center, Cincinnati, OH
Post-transplant cellular therapies have been used for treatment
of relapse and infections following BMT, and recently to convert
to full donor chimerism following non-myeloablative transplant.
Patients with NMD and mixed chimerism may also benefit from
DLI and avoid the morbidity and mortality of second BMT. We
reviewed our experience from 1998-2001 and report 12 pediatric
patients with NMD - immunologic (n=7) or metabolic (n=5) dis-
orders - who received DLI. Donor types include matched sibling
(n=1), haploidentical (n=1) and matched unrelated (n=10)
donors. The median time from BMT to DLI was 219 days
(range 32 to 908 days). Indications for DLI were mixed
chimerism (n=11) and treatment of infection (n=2); one patient
received DLI for both indications. A total of 32 infusions were
given, with a median of 2 DLI/patient (range 1-8). The median
percent donor chimerism prior to the first DLI was 17.5%
(range 0-90%). The median cell dose was 13.5 x 106 CD3+
cells/kg (range 0.2-74.5) for the first DLI and cumulative 35.10 x
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106 CD3+ cells/kg/patient (range 0.2-467). Three patients died
prior to 100 days post-DLI of infection (n=2) or GvHD (n=1).
Of evaluable patients 6/10 (60%) developed grade II-IV acute
GvHD, 3/10 (30%) grade III-IV and 4/9 (45%) chronic GvHD.
Median improvement of chimerism post-DLI was 49% (range 0-
100%) and 67% (immunologic = 3, metabolic = 3) had improved
and/or sustained donor chimerism. GvHD developed in 100% of
patients with improvement of chimerism; survival in this subset
of patients is 100% with a median follow-up of 10 months (range
4-41 months). Overall median survival is 8 months. In conclu-
sion, DLI for mixed chimerism in patients with NMD may be
effective, but is associated with a significant risk of GvHD. This
risk needs to be weighed against morbibity and mortality of sec-
ond BMT.
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PREVENTION OF MUCOSITIS BY IMMUNOL ORAL RINSE: FINAL
RESULTS OF A RANDOMIZED, VEHICLE CONTROLLED STUDY
Goldberg, S.L.1; Pineiro, L.2; Schuster, M.W.3; Coleman, M.3;
McCarthy, P.L.4; Fruchtman, S.M.5; Stadtmauer, E.A.6 1. Hackensack
University Medical Center, Hackensack, NJ; 2. Baylor University
School of Medicine, Dallas, TX; 3. Weil Medical College of Cornell
University, New York, NY; 4. Roswell Park Cancer Institute, Buffalo,
NY; 5. Mount Sinai School of Medicine, New York, NY; 6. University
of Pennsylvania, Philadelphia, PA
Background: Oral mucositis is a common BMT regimen related
toxicity.Methods: Randomized, double blinded, vehicle controlled
study. Results: 119 evaluable subjects received Immunol oral rinse
(BML Pharmaceuticals Inc, Manhasset NY; n=62) or vehicle con-
trol (antimicrobial containing; n=57) four times daily. Immunol
reduced overall days of mucositis and occurrence of any mucositis,
ulcerations, or erythema among hematologic transplants. Condi-
tioning regimen intensity was a signiﬁcant predictor of mucositis;
regimens containing either melphalan, etoposide, busulfan, or TBI
designated “high mucositis producing regimens (HMR)”. Immunol
reduced mucositis rates in HMR. Subjects with solid tumors or not
receiving HMR had low rates of mucositis, irrespective of random-
ization, diluting the overall population results (since patients not at
risk for mucositis could not further experience prevention bene-
ﬁts). For the entire study, Immunol yielded trends in reduced days
of mucositis (4.66 vs 6.12 days; p=0.097) and any mucositis event
(67.74% vs 75.44%; p=0.353).Conclusions: Immunol oral rinse is
an active preventative agent against oral mucositis, with beneﬁcial
effects noted in transplants for hematologic malignancies or using
High Mucositis Regimens.
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ETANERCEPT ADMINISTRATION FOR IDIOPATHIC PNEUMONIA SYN-
DROME AFTER ALLOGENEIC BMT
Yanik, G.A.; Hellerstedt, B.; Hutchinson, R.; Uberti, J.; Cooke, K.R.
University of Michigan Cancer Center, Ann Arbor, MI
Idiopathic pneumonia syndrome (IPS) refers to acute, non-
infectious pulmonary dysfunction that occurs after BMT. The
clinical response of IPS to standard therapy including high
dose steroids and broad-spectrum anti-microbial agents is lim-
ited and mortality rates of 50% to 70% have been reported.
Our laboratory has generated pre-clinical data that reveal an
important role for TNFα in the pathophysiology of IPS.
Based upon these findings, we administered etanercept
(Enbrel, Immunex Corp., Seattle WA), a FDA approved,
TNFα neutralizing agent, to three consecutive patients who
developed IPS after allogeneic BMT. All patients also received
tacrolimus and high dose steroids. Two patients received mis-
matched family member transplants and one received a
matched URD BMT. In 2 patients, the development of IPS
coincided with neutrophil engraftment. One patient was diag-
nosed with concurrent acute GVHD involving the gut, liver
and skin, whereas IPS developed in the setting of severe VOD
in the other two. Each patient had complete resolution of IPS
and no adverse drug reactions were observed. In two patients,
etanercept was discontinued after resolution of IPS because of
evidence for systemic infections that were ultimately success-
fully treated. Although each patient died from other BMT
related complications, the time from diagnosis of IPS to death
in these 3 patients was 111, 73, and 55 days respectively com-
pared to the median of 13 days in our historical controls.
Importantly, respiratory failure was not the primary cause of
death for any patient. In conclusion, etanercept, in conjunc-
tion with steroids and tacrolimus, was well tolerated and asso-
ciated with significant improvements in IPS within the first
week of therapy. These data suggest that etanercept may rep-
resent a safe, therapeutic option for patients with IPS and that
clinical trials studying etanercept for this indication are war-
ranted. A Phase I/II protocol is currently open at the Universi-
ty of Michigan.
